Please try another search
For the three months ended 30 June 2017, Dishman Pharmaceuticals&Chemicals Ltd revenues decreased 10% to RS3.4B. Net income applicable to common stockholders decreased 57% to RS130.2M. Revenues reflect CRAMS segment decrease of 9% to RS2.47B, Unallocate segment decrease of 4% to RS917M. Net income also reflects Other expenses increase of 9% to RS787.9M (expense), Depreciation and Amortization expense increase of 2% to RS514.1M (expense).
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Revenue | 3396.4 | 5342.2 | 3620.7 | 4365.5 |
Gross Profit | 2922.1 | 4168.2 | 2936.7 | 3447.1 |
Operating Income | 186.1 | 897 | 443.8 | 848.9 |
Net Income | 130.1 | 427.9 | 289.6 | 546.7 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Assets | 65934.3 | 30861.7 | ||
Total Liabilities | 17794.5 | 14086.5 | ||
Total Equity | 48139.8 | 16775.2 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review